BioSig Technologies (NASDAQ:BSGM) released its quarterly earnings results on Monday. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03), Fidelity Earnings reports.
BSGM stock opened at $6.42 on Wednesday. BioSig Technologies has a twelve month low of $3.50 and a twelve month high of $7.88.
In other BioSig Technologies news, CEO Kenneth L. Londoner bought 18,700 shares of BioSig Technologies stock in a transaction on Tuesday, January 22nd. The shares were acquired at an average price of $4.35 per share, for a total transaction of $81,345.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 26.70% of the company’s stock.
Several analysts recently weighed in on BSGM shares. Laidlaw set a $11.00 price target on BioSig Technologies and gave the company a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research lowered BioSig Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2019/04/17/biosig-technologies-bsgm-announces-quarterly-earnings-results-misses-expectations-by-0-03-eps.html.
BioSig Technologies Company Profile
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Recommended Story: Analyzing a company’s cash flow statement
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.